A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 19,873 shares of GRTS stock, worth $596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,873
Previous 22,073 9.97%
Holding current value
$596
Previous $13,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$0.45 - $0.71 $990 - $1,562
-2,200 Reduced 9.97%
19,873 $11,000
Q4 2023

Jan 16, 2024

SELL
$1.28 - $2.85 $4,480 - $9,975
-3,500 Reduced 13.69%
22,073 $45,000
Q3 2023

Oct 24, 2023

SELL
$1.19 - $2.26 $476 - $903
-400 Reduced 1.54%
25,573 $43,000
Q1 2023

Apr 14, 2023

BUY
$2.13 - $3.74 $1,433 - $2,517
673 Added 2.66%
25,973 $72,000
Q4 2022

Feb 08, 2023

BUY
$2.17 - $3.92 $5,425 - $9,800
2,500 Added 10.96%
25,300 $87,000
Q3 2022

Oct 25, 2022

BUY
$2.46 - $4.75 $5,166 - $9,975
2,100 Added 10.14%
22,800 $59,000
Q2 2022

Aug 12, 2022

BUY
$1.77 - $4.34 $7,611 - $18,662
4,300 Added 26.22%
20,700 $50,000
Q1 2022

May 11, 2022

BUY
$4.03 - $12.19 $6,851 - $20,723
1,700 Added 11.56%
16,400 $68,000
Q4 2021

Feb 08, 2022

SELL
$8.76 - $13.71 $178,266 - $278,998
-20,350 Reduced 58.06%
14,700 $189,000
Q3 2021

Nov 02, 2021

BUY
$6.41 - $13.54 $74,676 - $157,741
11,650 Added 49.79%
35,050 $379,000
Q2 2021

Aug 11, 2021

SELL
$8.13 - $10.2 $3,252 - $4,079
-400 Reduced 1.68%
23,400 $214,000
Q1 2021

May 14, 2021

BUY
$4.07 - $27.11 $18,722 - $124,706
4,600 Added 23.96%
23,800 $224,000
Q4 2020

Feb 12, 2021

BUY
$2.57 - $4.22 $16,841 - $27,653
6,553 Added 51.81%
19,200 $76,000
Q3 2020

Nov 04, 2020

BUY
$2.63 - $8.09 $33,261 - $102,314
12,647 New
12,647 $34,000

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.